Linvemastat not checked

Primevera Therapeutics, LLC. · FP-020

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Asthma (Diagnosis), Pulmonary Function, Moderate-to-Severe Asthma
Main trialPhase 2
“This study explores a potential new treatment for adults with moderate-to-severe asthma using a drug called linvemastat, which targets an enzyme linked to lung inflammation. Despite using standard asthma medications, many patients still struggle with symptoms, so researchers are testing whether linvemastat can improve lung function and reduce flare-ups. In a carefully controlled trial, subjects receive either one of two doses of the drug or a placebo, while continuing their usual treatments. Over 24 weeks, scientists monitor breathing capacity, symptom control, and safety to determine if…”In the company’s words, NCT07191535 on ClinicalTrials.gov
Other names
FP-020

Other drugs for Asthma (Diagnosis)

All 58 drugs for Asthma (Diagnosis)

Coming up1

Changes1

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting 1 Mar 2028 Effect of Linvemastat in Patients With Partially Controlled Asthma (syMMPonia)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow Linvemastat

Following is part of Solo: you see every change to Linvemastat the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in